These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32351189)

  • 21. Alzheimer disease: Non-pharmacological and pharmacological management of cognition and neuropsychiatric symptoms.
    Loi SM; Eratne D; Kelso W; Velakoulis D; Looi JC
    Australas Psychiatry; 2018 Aug; 26(4):358-365. PubMed ID: 29671334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Realistic expectations for treatment success in Alzheimer's disease.
    Geldmacher DS; Frolich L; Doody RS; Erkinjuntti T; Vellas B; Jones RW; Banerjee S; Lin P; Sano M
    J Nutr Health Aging; 2006; 10(5):417-29. PubMed ID: 17066215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From traditional European medicine to discovery of new drug candidates for the treatment of dementia and Alzheimer's disease: acetylcholinesterase inhibitors.
    Russo P; Frustaci A; Del Bufalo A; Fini M; Cesario A
    Curr Med Chem; 2013; 20(8):976-83. PubMed ID: 23210783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological treatment of dementia and mild cognitive impairment due to Alzheimer's disease.
    Popp J; Arlt S
    Curr Opin Psychiatry; 2011 Nov; 24(6):556-61. PubMed ID: 21934621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands.
    Iraji A; Khoshneviszadeh M; Firuzi O; Khoshneviszadeh M; Edraki N
    Bioorg Chem; 2020 Apr; 97():103649. PubMed ID: 32101780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential therapeutic agents against Alzheimer's disease from natural sources.
    Park SY
    Arch Pharm Res; 2010 Oct; 33(10):1589-609. PubMed ID: 21052936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent Advances in Multi-target Anti-Alzheimer Disease Compounds (2013 Up to the Present).
    Wang N; Qiu P; Cui W; Yan X; Zhang B; He S
    Curr Med Chem; 2019; 26(30):5684-5710. PubMed ID: 30501591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential therapeutic natural products against Alzheimer's disease with Reference of Acetylcholinesterase.
    Ahmed S; Khan ST; Zargaham MK; Khan AU; Khan S; Hussain A; Uddin J; Khan A; Al-Harrasi A
    Biomed Pharmacother; 2021 Jul; 139():111609. PubMed ID: 33915501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging drugs for progressive supranuclear palsy.
    Giagkou N; Stamelou M
    Expert Opin Emerg Drugs; 2019 Jun; 24(2):83-92. PubMed ID: 31007097
    [No Abstract]   [Full Text] [Related]  

  • 30. Multitarget drugs of plants origin acting on Alzheimer's disease.
    Russo P; Frustaci A; Del Bufalo A; Fini M; Cesario A
    Curr Med Chem; 2013; 20(13):1686-93. PubMed ID: 23410167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
    Korabecny J; Spilovska K; Mezeiova E; Benek O; Juza R; Kaping D; Soukup O
    Curr Med Chem; 2019; 26(30):5625-5648. PubMed ID: 29768996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging drug targets for Aβ and tau in Alzheimer's disease: a systematic review.
    West S; Bhugra P
    Br J Clin Pharmacol; 2015 Aug; 80(2):221-34. PubMed ID: 25753046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease.
    Sahoo AK; Dandapat J; Dash UC; Kanhar S
    J Ethnopharmacol; 2018 Apr; 215():42-73. PubMed ID: 29248451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease.
    Venneri A; McGeown WJ; Shanks MF
    Neuroreport; 2005 Feb; 16(2):107-10. PubMed ID: 15671856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New Drugs from Marine Organisms in Alzheimer's Disease.
    Russo P; Kisialiou A; Lamonaca P; Moroni R; Prinzi G; Fini M
    Mar Drugs; 2015 Dec; 14(1):5. PubMed ID: 26712769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacoeconomics of Alzheimer's disease (AD) treatment with cholinesterase inhibitors.
    Versijpt J
    Acta Neurol Belg; 2012 Jun; 112(2):141-5. PubMed ID: 22476975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Geroneuroprotectors: Effective Geroprotectors for the Brain.
    Schubert D; Currais A; Goldberg J; Finley K; Petrascheck M; Maher P
    Trends Pharmacol Sci; 2018 Dec; 39(12):1004-1007. PubMed ID: 30446211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
    Robert P
    Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.
    Hauber AB; Gnanasakthy A; Mauskopf JA
    Clin Ther; 2000 Apr; 22(4):439-51. PubMed ID: 10823365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.